Anthropic to develop its own drugs for neglected diseases
Get the Tech newsletter
Daily tech — startups, AI labs, chips, the launches that shape the next decade. Free.
- Anthropic announced at its "The Briefing: AI for Science" event that it will develop drugs of its own, with head of life sciences Eric Kauderer-Abrams saying the company would focus on "neglected" diseases.
- Anthropic also unveiled Claude Science, an "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, generates figures, and already counts a roster of biotech and pharma customers.
- Anthropic has been actively recruiting biologists, building its own wet labs, and currently lists several life sciences job openings, having reportedly poached researchers from Big Pharma and top academic institutions.
- Anthropic declined to specify target diseases, potential lab partnerships, or what it would do with any promising drug candidate, leaving most concrete details of the drug program undisclosed.
- Drug discovery experts including University College London's Matthew Todd and the University of Oxford's Frank von Delft stressed the field remains "a long way off" from AI-designed drugs reaching regulators, with no AI-designed drug yet approved by the FDA.
- Competing AI-drug efforts span Google's DeepMind spinoff Isomorphic Labs, Insilico, AI tools from OpenAI, Amazon, and Google, plus Big Pharma's internal programs, with AI now applied at "every single stage of drug discovery."
Why it matters: Anthropic will now sit in the unusual position of selling Claude Science tools to drugmakers while competing with those very same drugmakers, a tension no other frontier AI company has taken this publicly. The hiring and wet-lab buildout suggests serious intent, but experts interviewed stress that even frontier AI cannot shortcut the years of real-world clinical testing required — no AI-designed drug has yet reached FDA approval, making any payoff at least a decade away.
